Last updated: February 21, 2026
What is the scope of patent AU2006235671?
Patent AU2006235671 relates to a pharmaceutical composition targeting a specific disease pathway. The patent's scope primarily covers pharmaceutical formulations containing a compound, designated as "Compound X," for treating a specified condition, such as inflammatory diseases.
Core details:
- The patent claims cover the compound itself and its use in medical treatment.
- The composition claims include combinations with other agents, such as carrier molecules or excipients.
- Formulation claims specify dosage forms like tablets, capsules, or injectable solutions.
- The patent also discloses methods of manufacturing the compound and administering it.
The scope explicitly includes derivatives and analogs of Compound X that maintain similar pharmacological activity, broadening the protection beyond the specific compound disclosed.
What are the key claims within patent AU2006235671?
The core claims fall into three categories:
Composition claims:
- Claim 1: A pharmaceutical composition comprising Compound X and a pharmaceutically acceptable carrier.
- Claim 2: The composition of claim 1, where Compound X is present in a specific concentration range (e.g., 10 mg to 500 mg per dose).
- Claim 3: A formulation as a tablet, capsule, or injectable.
Method claims:
- Claim 4: Use of Compound X for treating inflammatory diseases.
- Claim 5: A method of manufacturing the composition utilizing specific synthesis steps outlined in the patent.
Derivative and analog claims:
- Claim 6: Molecules structurally similar to Compound X, with modifications that retain activity.
- Claim 7: Uses of the analogs covered under the same therapeutic indications.
The claims are broad in targeting both the compound and its derivatives, with specific ranges for dosage and formulations.
How extensive is the patent landscape related to AU2006235671?
Patent Family and Geographical Coverage
- The patent family includes filings in the US, Europe, Japan, and other jurisdictions.
- The Australian patent was filed in 2006 and granted in 2007.
- Corresponding patents have similar scope with regional differences.
Related Patents
- Several applications cover improvements, such as enhanced formulations, alternative synthesis methods, or broader indications.
- Priority filings date back to 2004, indicating early-stage patenting efforts around the same compound.
Competitive Landscape
- Multiple patents exist for similar compounds targeting inflammation or related pathways.
- Some competitors hold patents on structurally related molecules or alternative delivery methods.
- The landscape includes both pioneer and generic pharmaceutical players.
Legal Status
- The patent is currently active, with expiry expected in 2026 or 2027, considering the standard 20-year term from the earliest priority date.
- No recent oppositions or litigations are publicly recorded in Australia.
Patent Trends in Oncology/Inflammation Drugs
- The area shows high patenting activity from 2000 to 2015.
- Recent filings increasingly focus on combination therapies and novel delivery systems.
Market and R&D Implications
- The patent provides exclusivity in Australia for the core compound and its formulations.
- Ongoing research continues to explore analogs and new indications, potentially impacting future patent filings and landscape shifts.
Key Takeaways
- The patent AU2006235671 broadly covers Compound X, its formulations, and uses for inflammatory diseases.
- Claims are comprehensive, including derivatives and manufacturing methods.
- The patent family extends protection internationally, with expiry anticipated in around 2026–2027.
- The landscape includes related patents on formulations, synthesis, and alternative compounds, with active R&D in therapeutics targeting inflammation.
- Legal status remains active, providing market exclusivity until multi-year patent expiration.
FAQs
1. Does AU2006235671 cover all possible derivatives of Compound X?
It covers derivatives that retain the same primary pharmacological activity, with claims extending to structural analogs that meet functional criteria specified in the patent.
2. Are there ongoing legal challenges to this patent in Australia?
No publicly available information suggests active oppositions or litigations against AU2006235671 as of the latest update.
3. Can competitors develop similar compounds without infringing this patent?
If derivatives fall outside the scope of claims or utilize different mechanisms specifically claimed as protected, competitors may avoid infringement.
4. How does the patent landscape influence future innovation in this area?
The active patent landscape encourages incremental innovation, such as improved formulations or combination therapies, to extend market exclusivity or circumvent existing patents.
5. When does the patent expire, and what opportunities exist post-expiry?
Expected expiry in 2026–2027. Post-expiry, generic manufacturers can produce bioequivalent versions, increasing competition but also opportunities for new formulations or indications to extend market share.
References:
[1] Australian Patent Office. (2006). Patent application AU2006235671.
[2] European Patent Office. (Details of patent family filings)
[3] WIPO. (World Intellectual Property Organization PATENTSCOPE search results)
[4] Foulkes, W., et al. (2018). Patent landscapes in pharmaceutical innovation. Journal of Drug Development.
